Formula Anti-Stress (2021.)
Food supplement registered in Latvia
Register snapshot dated 2 May 2025. It does not establish the current status of the product.
- Number published by PVD
- 0000137/2021
- Type
- Food supplement
- Published status
- Status not provided in this export; the validity date is shown separately
- Licence holder
- name not reproduced (no recognised company form)
- Manufacturer
- name not reproduced (no recognised company form)
- Origin
- Latvija
- Register snapshot
- 2 May 2025
- Recommended daily intake (Latvian text)
- 1 tablete
- Published pack size
- tabletes pa 1287,5 mg
- Published packaging
- 30 vai 60 tabletes
This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.
The foreign register category does not determine the regulatory category of the product in France.
Published composition
| Published name | Published text and quantity | Recognised ingredient | Role or context |
|---|---|---|---|
| C VITAMĪNS | vitamins ; C VITAMĪNS ; 350 ; mg | Vitamine C | Vitamin or mineral |
| E VITAMĪNS | vitamins ; E VITAMĪNS ; 27 ; mg α-TE | Vitamine E | Vitamin or mineral |
| NIACĪNS | vitamins ; NIACĪNS ; 20 ; mg NE | Vitamine B3 (niacine) | Vitamin or mineral |
| PANTOTĒNSKĀBE | vitamins ; PANTOTĒNSKĀBE ; 15 ; mg | Acide pantothénique (vitamine B5) | Vitamin or mineral |
| B12 VITAMĪNS | vitamins ; B12 VITAMĪNS ; 6 ; μg | Vitamine B12 | Vitamin or mineral |
| B6 VITAMĪNS | vitamins ; B6 VITAMĪNS ; 3 ; mg | Vitamine B6 | Vitamin or mineral |
| B1 VITAMĪNS | vitamins ; B1 VITAMĪNS ; 3 ; mg | Vitamine B1 (thiamine) | Vitamin or mineral |
| B2 VITAMĪNS | vitamins ; B2 VITAMĪNS ; 2 ; mg | Vitamine B2 (riboflavine) | Vitamin or mineral |
| FOLSKĀBE | vitamins ; FOLSKĀBE ; 400 ; μg | Folates (vitamine B9) | Vitamin or mineral |
| Kalcijs | minerals ; Kalcijs ; 130 ; mg | Calcium | Vitamin or mineral |
| Magnijs | minerals ; Magnijs ; 25 ; mg | Magnésium | Vitamin or mineral |
| Cinks | minerals ; Cinks ; 25 ; mg | Zinc | Vitamin or mineral |
| Ārstniecības baldriāns | plants ; Ārstniecības baldriāns ; Valeriana officinalis ; ekstrakts ; 100 ; mg | valeriana officinalis | Plant |
| Pasiflora | plants ; Pasiflora ; Passiflora incarnata ; ekstrakts ; 2 ; mg | passiflora incarnata | Plant |
| Ārstniecības melisa | plants ; Ārstniecības melisa ; Melissa officinalis ; ekstrakts ; 2 ; mg | melissa officinalis | Plant |
| Kumelīte | plants ; Kumelīte ; Matricaria chamomilla ; ekstrakts ; 1 ; mg | matricaria chamomilla | Plant |
| Eleiterokoks | plants ; Eleiterokoks ; Eleutherococcus senticosus ; ekstrakts ; 1 ; mg | eleutherococcus senticosus | Plant |
| Apinis | plants ; Apinis ; Humulus lupulus ; ekstrakts ; 1 ; mg | humulus lupulus | Plant |
| Holīns | otherNutrients ; Holīns ; 5 ; mg | Not recognised | Role not identified |
| Paraaminobenzoskābe | otherNutrients ; Paraaminobenzoskābe ; 5 ; mg | Not recognised | Role not identified |
| Maltodekstrīns | otherIngredients ; Maltodekstrīns ; - ; cita | Not recognised | Role not identified |
| Ciete | otherIngredients ; Ciete ; - ; cita | Not recognised | Role not identified |
| 194 | foodAdditives ; 194 | Not recognised | Role not identified |
| 199 | foodAdditives ; 199 | Not recognised | Role not identified |
| 205 | foodAdditives ; 205 | Not recognised | Role not identified |
| 258 | foodAdditives ; 258 | Not recognised | Role not identified |
| 2 | foodAdditives ; 2 | Not recognised | Role not identified |
Quantities are reproduced as published. The export does not specify their basis: the recommended daily intake cannot be used to calculate a daily dose. No daily dose is estimated. Latvian names are retained without translation.
Manufacturer countries
Latvija
French and European references for recognised ingredients
- Conditions légales
Valeriana officinalis L.: L'absence de valépotriates doit être prouvée par des rapports d'analyse. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Amount read: 130 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 800 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSAEuropean Food Safety Authority. reference for adults: 2,500 mg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
Amount read: 25 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 300 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSA reference for adults: 250 mg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
French reference: maximum dose of 15 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSA reference for adults: 25 mg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
Amount read: 100 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
valeriana officinalis is on the list of plants allowed in food supplements (Order of 24 June 2014). Restriction: L'absence de valépotriates doit être prouvée par des rapports d'analyse. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans.
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Amount read: 2 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
passiflora incarnata is not on the plant list of the Order of 24 June 2014: this is not a prohibition (a product legally sold in another Union country may contain it).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
melissa officinalis is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Amount read: 1 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
matricaria chamomilla is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
eleutherococcus senticosus is on the list of plants allowed in food supplements (Order of 24 June 2014).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
humulus lupulus is not on the plant list of the Order of 24 June 2014: this is not a prohibition (a product legally sold in another Union country may contain it).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Amount read: 5 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 350 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 180 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
Amount read: - cita. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 27 mg α-TE. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Ambiguous amount: no numerical value retained for comparison.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 20 mg NE. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Vitamin B3 with no form specified: the maximum dose in France is 54 mg for nicotinamide and 8 mg for nicotinic acid; the form is on the label.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 15 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 6 µg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 3 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 2 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSA reference for adults: 12 mg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
Amount read: 400 µg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 200 µg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSA reference for adults: 1,000 µg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
Unrecognised ingredients are not assessed. The absence of a signal does not establish product compliance.
Official source
Internet Archive copy dated 3 May 2025
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ārstniecības baldriāns
Read the warning, when it applies and the studies cited
Valerian - VALERIANA OFFICINALIS
Route of administration: Oral
Cautions and warnings
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Mills et al. 2006; Blumenthal et al. 2003; Barnes et al. 2002).
Sources cited by Health Canada (3)
- Barnes J, Anderson LA, Phillipson JD. Herbal Medicines: A guide for healthcare professionals. 2nd ed. London (UK): Pharmaceutical Press; 2002.
- Blumenthal M, Hall T, Goldberg A, Kunz T, Dinda K, Brinckmann J, Wollschlaeger B, editors. 2003. The ABC Clinical Guide to Herbs: Valerian. Austin, Texas: American Botanical Council.
- Mills E, Dugoua J, Perri D, Koren G. 2006. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (GB): Taylor and Francis Medical.
When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010; Gennaro et al. 2000).
Sources cited by Health Canada (2)
- Gennaro AR, Marderosian AHD, Hanson GR, Medwick T, editors. 2000. Remington: The Science and Practice of Pharmacy, 20th edition. Philadelphia (PA): Lippincott Williams & Wilkins.
- Brinker F. Herb Contraindications and Drug Interactions, 4e édition. Sandy (OR): Eclectic Medical Publications. 2010.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2016; ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (3)
- Bradley PR, editor. 1992. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
- EMA 2016. European Medicines Agency. Community Monograph on Valeriana Officinalis L., Radix. London (GB): EMEA Committee on Herbal Medicinal Products (HMPC), 02 Febuary 2016. [Accessed 2023 October 27]. Available from: https://www.ema.europa.eu/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (EMA 2016; Berardi et al. 2002; Dipiro et al. 2002).
Sources cited by Health Canada (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
- Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. 2002. Pharmacotherapy: A Pathophysiologic Approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.
- EMA 2016. European Medicines Agency. Community Monograph on Valeriana Officinalis L., Radix. London (GB): EMEA Committee on Herbal Medicinal Products (HMPC), 02 Febuary 2016. [Accessed 2023 October 27]. Available from: https://www.ema.europa.eu/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf
Condition of application: Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Pasiflora
Read the warning, when it applies and the studies cited
PASSIONFLOWER -PASSIFLORA INCARNATA
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).
Sources cited by Health Canada (2)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach, 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002
Condition of application: Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).
Sources cited by Health Canada (1)
- EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf
When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).
Sources cited by Health Canada (1)
- EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2014).
Sources cited by Health Canada (1)
- EMA 2014. European Medicines Agency. Community Monograph on. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 20 September 2016. [Accessed 2023 October 1]. Available from: https://www.ema.europa.eu/documents/herbal-summary/passion-flower-summary-public_en.pdf
- Ārstniecības melisa
Read the warning, when it applies and the studies cited
LEMON BALM -MELISSA OFFICINALIS
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).
Sources cited by Health Canada (1)
- EMA 2014. European Medicines Agency. Melissae folium.. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 16 June2014. [Accessed 2023 October 27]. Available at: https://www.ema.europa.eu/en/medicines/herbal/melissae-folium
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).
Sources cited by Health Canada (1)
- EMA 2014. European Medicines Agency. Melissae folium.. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 16 June2014. [Accessed 2023 October 27]. Available at: https://www.ema.europa.eu/en/medicines/herbal/melissae-folium
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Kumelīte
Read the warning, when it applies and the studies cited
GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Oral
Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000; WHO 1999; Bradley 1992).
Cautions and warnings
When using this product exercise caution if you drive or use machinery as you may experience drowsiness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Health Canada monograph dated 19 December 2025
German Chamomile - Matricaria Chamomilla Topical
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Health Canada monograph dated 31 January 2025
GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Buccal
Route of administration: Buccal (ESCOP 2003; Blumenthal et al. 2000; Bradley 1992)
Cautions and warnings
Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Eleiterokoks
Read the warning, when it applies and the studies cited
ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS
Route of administration: Oral (ESCOP 2003; Bradley 1992)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).
Sources cited by Health Canada (2)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.
Contraindications
Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).
Sources cited by Health Canada (5)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
- Mills S, Bone K. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone; 2000.
- Apinis
Read the warning, when it applies and the studies cited
HOPS - HUMULUS LUPULUS
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).
Sources cited by Health Canada (2)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.; 2002.
Condition of application: Other uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; McGuffin et al. 1997).
Sources cited by Health Canada (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Brinker F. Herb Contraindications and Drug interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2014 : European Medicines Agency. Draft Community Herbal Monograph on Humulus lupulus L., Flos. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 6 Mai 2014. [Consulté le 14 septembre 2023]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf
When using this product exercise caution if you drive or use machinery as this product may cause drowsiness (EMA 2014).
Sources cited by Health Canada (5)
- EMA 2014: European Medicines Agency. Draft Community Herbal Monograph on Humulus lupulus L., Flos. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 6 May 2014. [Accessed 2023 September 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3e édition. London (UK): The Pharmaceutical Press; 2007.
- Brinker F. Herb Contraindications and Drug interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.